-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US2975841048 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | None |
|---|---|
| PE Ratio | None |
| Beta | -0.09 |
| Target Price | None |
| Dividend Yield | None |
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ESLAW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025